Market Place
Sourcing Support
Dr. Reddy’s launches Toripalimab under brand name Zytorvi in India
30 Nov 2024 //
PRESS RELEASE
Junshi Biosciences Gets UK MHRA Approval for Toripalimab
16 Nov 2024 //
GLOBENEWSWIRE
Junshi Biosciences’ Toripalimab Gains Approval In India, Hong Kong
16 Oct 2024 //
BIOSPECTRUM
Junshi Biosciences Toripalimab Approved For Marketing In India
15 Oct 2024 //
GLOBENEWSWIRE
Harbour BioMed Publishes Phase I Study Results For Porustobart
09 Oct 2024 //
PR NEWSWIRE
Junshi Announces EC Approval for Marketing of Toripalimab
24 Sep 2024 //
GLOBENEWSWIRE
Coherus`s Loqtorzi (toripalimab) Receives Approval in Europe
19 Sep 2024 //
EMA
Junshi`s Toripalimab sNDA Accepted For First-Line Melanoma Treatment
12 Aug 2024 //
GLOBENEWSWIRE
Junshi`s Toripalimab Combo NDA Accepted For Liver Cancer
17 Jul 2024 //
GLOBENEWSWIRE
Junshi Biosciences Receives sNDA Approval for Toripalimab in Advanced TNBC
25 Jun 2024 //
GLOBENEWSWIRE
Junshi Announces sNDA Approval For Toripalimab in 1st-Line Lung Cancer
18 Jun 2024 //
GLOBENEWSWIRE
Junshi, Coherus move Loqtorzi closer to another approval
13 Jun 2024 //
FIERCE PHARMA
Junshi Biosciences Announces Ph3 Study of Toripalimab Combined with Bevacizumab
11 Jun 2024 //
GLOBENEWSWIRE
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
09 May 2024 //
GLOBENEWSWIRE
Coherus, CRI Combo Trial For Ovarian Cancer Treatment
08 May 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
24 Apr 2024 //
GLOBENEWSWIRE
SEC recommends approval to Dr Reddy`s to import & markettoripalimab
18 Apr 2024 //
PHARMABIZ
Junshi Bio Announces Approval of the sNDA for Toripalimab for Renal Cancer
07 Apr 2024 //
GLOBENEWSWIRE
Junshi Biosciences Announces Toripalimab™s NDA Accepted
01 Feb 2024 //
GLOBENEWSWIRE
Junshi Announces JAMA Publication from Phase 3 of Perioperative Toripalimab
17 Jan 2024 //
GLOBENEWSWIRE
Junshi Announces Publication of Results from Phase 3 Trial of Toripalimab
09 Jan 2024 //
GLOBENEWSWIRE
INOVIO and Coherus Announce Clinical Collaboration
04 Jan 2024 //
PR NEWSWIRE
Junshi Announces Approval of Supplemental New Drug Application for Toripalimab
02 Jan 2024 //
GLOBENEWSWIRE
Junshi Announces Chemical Entity Application for Toripalimab Accepted by TGA
01 Dec 2023 //
GLOBENEWSWIRE
Coherus and Junshi Bio Announce Publication of Positive Results of LOQTORZI
28 Nov 2023 //
GLOBENEWSWIRE
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI
27 Oct 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
19 Jul 2023 //
GLOBENEWSWIRE
China’s NMPA Accepts sNDA for Frontline Toripalimab & Axitinib in Metastatic RCC
12 Jul 2023 //
RAPS
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab
11 Jul 2023 //
GLOBENEWSWIRE
Junshi Announces Initiation of Ph3 Study of Tifcemalimab plus Toripalimab
29 Jun 2023 //
GLOBENEWSWIRE
Coherus Announces Positive Overall Survival Results of JUPITER-02 Phase 3 Trial
05 Jun 2023 //
GLOBENEWSWIRE
FDA inspection of China-based site making Coherus` drug ends with 3 observations
31 May 2023 //
ENDPTS
Harbour reports results from HCC combo therapy trial
29 May 2023 //
CLINICAL TRIALS ARENA
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart
28 May 2023 //
PR NEWSWIRE
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with NSCLC
25 May 2023 //
PR NEWSWIRE
Junshi Announces Acceptance of sNDA for Toripalimab with Chemotherapy
23 May 2023 //
GLOBENEWSWIRE
Junshi Biosciences Announces Collaboration with Dr. Reddy™Toripalimab
07 May 2023 //
GLOBENEWSWIRE
Junshi Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab
27 Apr 2023 //
GLOBENEWSWIRE
Coherus & Junshi Announce Toripalimab Studies to be Presented at 2023 ASCO
27 Apr 2023 //
GLOBENEWSWIRE
Junshi Announces Toripalimab plus Chemotherapy Significantly Improved (EFS)
20 Apr 2023 //
GLOBENEWSWIRE
Junshi Bio Announces Acceptance of the Supplemental NDA for Toripalimab
11 Apr 2023 //
GLOBENEWSWIRE
Junshi & Coherus Announce Positive Final Overall Survival Results of JUPITER-02
15 Feb 2023 //
GLOBENEWSWIRE
Junshi says toripalimab succeeded in Phase III perioperative NSCLC study
19 Jan 2023 //
GLOBENEWSWIRE
Hikma & Junshi Biosciences sign exclusive licensing agreementfor cancer treatment drug toripalimab
27 Dec 2022 //
PRESS RELEASE
Junshi Biosciences & Hikma Sign Exclusive Licensing Agreement for Toripalimab
26 Dec 2022 //
GLOBENEWSWIRE
Coherus & Junshi Biosciences Share Update on the FDA Review BLA for Toripalimab
24 Dec 2022 //
GLOBENEWSWIRE
Junshi Announces Submission of a Marketing Authorization EMAfor Toripalimab
14 Nov 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination
20 Sep 2022 //
GLOBENEWSWIRE
Junshi Biosciences Receives Orphan Designation from the EC for Toripalimab
21 Jul 2022 //
GLOBENEWSWIRE
Two months after CRL, FDA accepts Coherus, Junshi`s resubmission of Toripalimab
07 Jul 2022 //
ENDPTS
Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology at ASCO
06 Jun 2022 //
GLOBENEWSWIRE
I-Mab, Junshi`s cancer combo worked best as first-line treatment
28 May 2022 //
FIERCEBIOTECH
Junshi Nabs NMPA Approval of sNDA for Toripalimab plus Paclitaxel and Cisplatin
16 May 2022 //
GLOBENEWSWIRE
Junshi Bio, Coherus Present Results of PIII Study of Toripalimab at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Another China-developed PD-1 faces possible delay
31 Mar 2022 //
FIERCEPHARMA
Coherus and Junshi uncork win for PD-1 drug in esophageal cancer
05 Mar 2022 //
ENDPTS
